Clinical trialNCT00822094CompletedPhase 2Interventional

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

SponsorJazz PharmaceuticalsEnrollment126Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens. The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jonathan Kolitz, MD
North Shore University Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

42 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Vancouver General Hospital/ British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Cancer Care Manitoba
Winnipeg, Manitoba, Canada

France

Service Des Maladies Du Sang Chu de Lille, Hopital Claude Huriez
Lille, France
Service Des Maladies Du Sang Hopital Haut-Leveque
Pessac, France
Service D'Hématologie Chu Toulouse-Hôpital Purpan
Toulouse, France
Service D'Hématologie Et Médecine Interne Chu de Nancy-Hôpital de Brabois
Vandœuvre-lès-Nancy, France

Poland

Klinika Hematologii I Transplantologii
Gdansk, Poland
Wojewódzki Szpital Specjalistyczny Im. M. Kopernika
Lodz, Poland
Oddział Hematologii
Opole, Poland
Instytut Hematologii I Transfuzjologii
Warsaw, Poland
Akademia Medyczna We Wroclawlu
Wroclaw, Poland

United States

Arizona Cancer Center
Tucson, Arizona, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Ucla
Los Angeles, California, United States
Uc Davis Cancer Center
Sacramento, California, United States
University of Colorado Cancer Center
Aurora, Colorado, United States
Northwestern University Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Chicago Medical Center Section of Hematology/oncology
Chicago, Illinois, United States
St. Francis Cancer Center
Beech Grove, Indiana, United States
University of Louisville Brown Cancer Center
Louisville, Kentucky, United States
Maine General Medical Center Harold Alfond Center for Cancer Care
Waterville, Maine, United States
Johns Hopkins University
Baltimore, Maryland, United States
St. Louis University Medical Center
St Louis, Missouri, United States
the Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey, United States
North Shore Lij Center for Advanced Medicine Monter Cancer Center
Lake Success, New York, United States
New York Medical College
New York, New York, United States
Weil Cornell Medical Center
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Blumenthal Cancer Center/mecklenburg Medical Group
Charlotte, North Carolina, United States
Duke Comprehensive Cancer Center
Durham, North Carolina, United States
Jewish Hospital of Cincinatti
Cincinnati, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
Oncology and Hematology at Lehigh Valley
Bethlehem, Pennsylvania, United States
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States
Utmb Comprehensive Cancer Center
Galveston, Texas, United States
M.D. Anderson Cancer Center
Houston, Texas, United States
Joe Arrington Cancer Center
Lubbock, Texas, United States
Texas Tech University Health Sciences Center
Lubbock, Texas, United States
Cancer Therapy and Research Center at the University of Tx Health Science Center
San Antonio, Texas, United States

2 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CPX-351Intensive Salvage Therapy

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 28 Feb 2009
Primary completion: 31 Dec 2011
Completion: 31 Jan 2012
Last update posted: 24 Nov 2017
Registered enrollment: 126
Registry id: NCT00822094

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.